南京医科大学学报（英文版）2008，Vol.22Issue(5)：269-272,4.
Dosimetry for 125I radioactive seed implantation therapy for hepatocellular carcinoma
Dosimetry for 125I radioactive seed implantation therapy for hepatocellular carcinoma
Jin Lü 1Xiufeng Cao1
作者信息
- 1. Oncology Center, the Nanjing First Hospital Affiliated to Nanjing Medical University, Nanjing 210006, Jiangsu Province, China
- 折叠
摘要
Abstract
Hepatocellular carcinoma (HCC) is an aggressive malignancy. Early lesions respond well to hepatic resection or liver transplantation.However, only a few of HCC patients are suitable for surgical intervention. External beam radiation and chemotherapy is poorly efficacious.In the last 20 years, HCCs belonging to the radiosensitive tumor group has been confirmed. Along with the development of new radiotherapy technology and facilities, the research about brachytherapy(especially 125I seed implantation therapy) has provoked more interests in the world. Radioactive seed implantation therapy is a form of interstitial brachytherapy, with the property of local "conformal radiotherapy" and the advantages of minimal invasion, convenience, high performance, and minimal adverse effects. It is a promising therapy for HCC, however the dosimetry hasn't yet been identified and lacks verification in prospective research. This report aims to further explore the best prescription dose and radioactivity for 125I interstitial implantation brachytherapy for HCC.关键词
carcinoma. hepatocellular/radiotherapy/brachytherapy/radioactive seeds/125IKey words
carcinoma. hepatocellular/radiotherapy/brachytherapy/radioactive seeds/125I分类
医药卫生引用本文复制引用
Jin Lü,Xiufeng Cao..Dosimetry for 125I radioactive seed implantation therapy for hepatocellular carcinoma[J].南京医科大学学报（英文版）,2008,22(5):269-272,4.
